Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that these products are safe, of high quality and effective for their intended use. This Act was introduced to address the need for a comprehensive framework governing the importation, manufacture, advertising, and supply of therapeutic goods, including medicines, medical devices, and blood and blood components. The Act is administered by the Therapeutic Goods Administration (TGA), an agency within the Department of Health, and its policy objective is to protect public health by regulating therapeutic goods. The TGA ensures that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy, thereby safeguarding consumers from potentially harmful products. The enactment of this Act by the Australian Parliament aimed to fill a critical gap in the regulation of therapeutic goods, providing a robust legal foundation for the oversight of these products. The Act empowers the TGA to issue licences to manufacturers, ensuring that only those who meet stringent regulatory standards are permitted to produce therapeutic goods for distribution in Australia. This legislative measure is fundamental in maintaining public confidence in the safety and efficacy of the therapeutic products available in the market.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Department of Health, applies to any entity or person involved in the manufacture, supply, or importation of therapeutic goods within Australia. This encompasses a wide range of products including medicines, medical devices, blood, and tissues, ensuring they meet safety, quality, and efficacy standards before entering the market. The Act applies nationally across the Commonwealth, and its jurisdiction extends to regulating therapeutic goods to protect public health. The Act includes provisions for granting licences to manufacturers, as evidenced by the example of the licence granted to Active Display Group, ensuring compliance with the stringent regulatory requirements for manufacturing therapeutic goods. The Act also includes mechanisms for exclusions, exemptions, or thresholds which may apply depending on the specific therapeutic goods in question. The application and enforcement of the Act may be extended or restricted through subordinate instruments, which provide additional detail and operational guidelines for compliance.

Key Provisions

The Therapeutic Goods Act 1989, specifically under section 38, outlines the process for granting a Licence to Manufacture Therapeutic Goods. The act mandates that the Secretary of the Department of Health, Therapeutic Goods Administration, must issue a written notice to the party granted such a licence. This is exemplified in the Gazette publication of 12 April 2021, which notifies the public that Active Display Group, located at 1-13 Childs Road, Chipping Norton, NSW, 2170, has been granted Licence No. MI-2020-LI-08352. This licence permits the company to manufacture therapeutic goods, subject to the terms and conditions outlined in the licence itself. The obligations imposed by the Therapeutic Goods Act 1989 on entities granted a manufacturing licence are comprehensive. They include adherence to Good Manufacturing Practice (GMP) standards, which are designed to ensure that therapeutic goods are produced in a consistent and controlled manner that ensures quality. The licensed entity must maintain records, such as those of production, quality control, and distribution, to demonstrate compliance with the Act. Additionally, the entity must notify the Therapeutic Goods Administration of any changes in the manufacturing process or premises, and ensure that their facilities and equipment are regularly inspected and maintained to meet the required standards. Breaches of the obligations outlined in the Therapeutic Goods Act 1989 can result in serious consequences. The Act provides for both civil and criminal penalties for non-compliance. For instance, a person who knowingly contravenes the Act may be liable to a civil penalty, with the maximum penalty being $1,110,000 for a corporation. Furthermore, individuals who are responsible for a contravention may face personal fines of up to $222,000 and imprisonment for up to five years. The Therapeutic Goods Administration has the authority to take enforcement actions, which may include the suspension or cancellation of the licence, thereby preventing the manufacture of non-compliant therapeutic goods. The severity of the penalties underscores the importance of adhering to the Act’s requirements to protect public health and safety.